Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gonda, Kohsuke ^a   Miyashita, Minoru ^a   Higuchi, Hideo ^b   Tada, Hiroshi ^a   Watanabe, Tomonobu M ^c   Watanabe, Mika ^d   Ishida, Takanori ^a   Ohuchi, Noriaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERSTITIAL COLLAGENASE; MONOCLONAL ANTIBODY; PROTEINASE ACTIVATED RECEPTOR 1; QUANTUM DOT;

ADULT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CELL MOTION; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; POSTOPERATIVE CARE; PROCEDURES; PROGNOSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE CARE; PROGNOSIS; QUANTUM DOTS; RECEPTOR, ERBB-2; RECEPTOR, PAR-1;

EID: 84942083617     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14322     Document Type: Article

References (37)

1. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572 (2002).
2. Schedin, P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6, 281-291 (2006).
3. McCarthy, N. Metastasis: Influencing bad behaviour. Nat Rev Cancer 9, 609 (2009).
4. Mego, M., Mani, S. A. & Cristofanilli, M. Molecular mechanisms of metastasis in breast cancer - clinical applications. Nat Rev Clin Oncol 7, 693-701 (2010).
5. Ravdin, P. M. & Chamness, G. C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 159, 19-27 (1995).
6. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, N.Y.) 235, 177-182 (1987).
7. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20, 719-726 (2002).
8. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England journal of medicine 353, 1659-1672 (2005).
9. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine 353, 1673-1684 (2005).
10. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine 367, 1783-1791 (2012).
11. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology 14, 461-471 (2013).
12. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28, 2784-2795 (2010).
13. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98, 10869-10874 (2001).
14. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100, 8418-8423 (2003).
15. Even-Ram, S. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4, 909-914 (1998).
16. Boire, A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005).
17. Arora, P., Ricks, T. K. & Trejo, J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 120, 921-928 (2007).
18. Booden, M. A., Eckert, L. B., Der, C. J. & Trejo, J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 24, 1990-1999 (2004).
19. Seeley, S. et al. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem Biol 10, 1033-1041 (2003).
20. Nelson, A. R., Fingleton, B., Rothenberg, M. L. & Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18, 1135-1149 (2000).
21. Yamamoto, A. et al. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer 103, 822-828 (2003).
22. Camp, R. L., Chung, G. G. & Rimm, D. L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8, 1323-1327 (2002).
23. Camp, R. L., Dolled-Filhart, M., King, B. L. & Rimm, D. L. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer research 63, 1445-1448 (2003).
24. Gonda, K., Watanabe, T. M., Ohuchi, N. & Higuchi, H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. J Biol Chem 285, 2750-2757 (2010).
25. Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. & Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature biotechnology 22, 969-976 (2004).
26. Lidke, D. S. et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nature biotechnology 22, 198-203 (2004).
27. Wu, X. et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature biotechnology 21, 41-46 (2003).
28. Tada, H., Higuchi, H., Wanatabe, T. M. & Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 67, 1138-1144 (2007).
29. Tan, Y. H. et al. A nanoengineering approach for investigation and regulation of protein immobilization. ACS Nano 11, 2374-2384 (2008).
30. Tay, C. Y. et al. Nanoparticles strengthen intracellular tension and retard cellular migration. Nano Letters 14, 83-88 (2014).
31. Tay, C. Y., Setyawati, M. I., Xie, J., Parak, W. J., & Leong, D. T. Back to basics: Exploiting the innate physico-chemical characteristics of nanomaterials for biomedical applications. Adv. Funct. Mater. 24, 5936-5955 (2014).
32. Kurebayashi, J. et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 79, 707-717 (1999).
33. Watanabe, T. M. & Higuchi, H. Stepwise movements in vesicle transport of HER2 by motor proteins in living cells. Biophys J 92, 4109-4120 (2007).
34. Hamada, Y. et al. In vivo imaging of the molecular distribution of the VEGF receptor during angiogenesis in a mouse model of ischemia. Blood 118, e93-e100 (2011).
35. Gonda, K. et al. Development of a quantitative diagnostic method of estrogen receptor expression levels by immunohistochemistry using organic fluorescent material-assembled nanoparticles. Biochem Biophys Res Commun 426, 409-414 (2012).
36. Li-Shishido, S., Watanabe, T. M., Tada, H., Higuchi, H. & Ohuchi, N. Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining. Biochem Biophys Res Commun 351, 7-13 (2006).
37. Hikage, M. et al. Nano-imaging of the lymph network structure with quantum dots. Nanotechnology 21, 185103 (2010).